Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis

Dermatology

Volumn 215, Issue 4, 2007, Pages 325-330

  Zuberbier, Torsten ^a   Heinzerling, Lucie ^a   Bieber, Thomas ^b   Schauer, Uwe ^c   Klebs, Sven ^d   Bräutigam, Matthias ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Eczema

Indexed keywords

PIMECROLIMUS; PREDNICARBATE; STEROID;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; BLEPHARITIS; BURN; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HERPES SIMPLEX; HUMAN; IMPETIGO; KERATITIS; MAJOR CLINICAL STUDY; MALE; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHOTOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADOLESCENT; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; OINTMENTS; PREDNISOLONE; TACROLIMUS; TREATMENT OUTCOME;

EID: 34948905255     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107627     Document Type: Article

References (17)

1. Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, et al: The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004;151:3-27.
2. Paul C, Graeber M, Stuetz A: Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 2000;9:69-77.
3. NICE: Appraisal consultation document: tacrolimus and pimecrolimus for atopic eczema. NICE Technology Appraisal 2004, No 82.
4. Queille C, Pommarede R, Saurat JH: Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984;1:246-253.
5. Lubach D, Gruter H, Behl M, Narel C: Investigations on the development and regression of corticosteroid-induced thinning of the skin in various parts of the human body during and after topical application of amcinonide. Dermatologica 1989;178:93-97.
6. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271-277.
7. Rajka G, Langeland T: Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:13-14.
8. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-18.
9. Lewis-Jones MS, Finlay AY: The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995;132:942-949.
10. McKenna SP, Whalley D, Dewar AL, Erdman RA, Kohlmann T, Niero M, et al: International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res 2005;14:231-241.
11. Darsow U, Lübbe J, Taïeb J, Seidenari S, Wollenberg A, Calza AM, Giusti F, Ring J: Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:286-295.
12. Simon D, Lubbe J, Wuthrich B, Wiesner A, Weber MM, Laffitte E, Anliker MD, Schoni MH, Braathen LR, Schmid-Grendelmeier P, Gilgen Bobalj N, Schneider D: Benefits from the use of pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice: analysis of a Swiss cohort. Dermatology 2006;213:313-318.
13. Kunz B, Oranje AP, Labreze L, Ring J, Taïeb A: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
14. Berth-Jones J: Six Area Six Sign AD (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996;135(suppl 48):25-30.
15. Grimalt R, Mengeaud V, Cambazard F, Study Investigators' Group: The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007;214:61-67.
16. McKenna SP, Whalley D, de Prost Y, Staab D, Huels J, Paul CF, van Assche D: Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol 2006;20:248-254.
17. Eichenfield LF, Diamant T, de Proust I, Puig L, Paul C: Clinical management of atopic eczema with primecrolimus cream 1% (Elidel®) in paediatric patients. Dermatology 2007;215(suppl 1):3-17.